Rehabilitation Program on Genetic & Degenerative Ataxia

Status Not yet recruiting

Clinical Trial Summary

Cerebellar ataxia is a pathology linked to the lesion of the cerebellum or the afferent and/or efferent cerebellar pathways. The aetiology can be an acquired cerebral lesion, following a chemical poisoning or a genetic degenerative lesion (for example : Friedreich's ataxia, spinocerebellar ataxias, etc.). As reported by the latest estimate available, genetic degenerative cerebellar ataxias affect approximately 6,000 patients in France (Orpha.net). Symptoms suffered by ataxic patients are : problems and gait disorders along with difficulties in coordination resulting in ataxia, uncoordinated movements. These symptoms cause a decrease in the quality of life on patients with spinocerebellar ataxia. The symptoms improvement linked to the cerebellar syndrome is based on rehabilitation that can be supplemented by use of technical aids. Current scientific knowledge confirms that intensive rehabilitation by physiotherapy and occupational therapy in patients with degenerative ataxias improves cerebellar symptoms. Nevertheless, the choice rehabilitation technique stay at the appreciation of the therapist. From the observation, the investigators have designed an intensive multidisciplinary rehabilitation program, called PAMPERO, with partner patients member of two genetic degenerative ataxia patient organisations. This 5-weeks program has been used in clinic during 3 years on 28 patients. It appears to be the only one in France. The preliminary results show a positive effect on ataxia symptom. Nevertheless, the duration of the benefice over time and the effect on the quality of life stay unknown. However, the quality of life is mainly affected by the participation restriction due to the risk of falling. The most frequent complaint from partner patient is the diminution of the social interaction resulting of the incapacity to move without risk. The present protocol aimed at evaluating the Rehabilitation Program in collaboration with partner patient on the symptom intensity, activity and quality of life on genetic and degenerative ataxia. This PAMPERO program's effect will be assessed by comparing the difference of Intensity of symptom measured by to Scale for the Assessment and Rating of Ataxia (SARA) at inclusion and 3 months after the end of rehabilitation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06089863
Study type	Interventional
Source	Hospices Civils de Lyon
Contact	Lucas PIGNON
Phone	04 78 86 50 58
Email	lucas.pignon@chu-lyon.fr
Status	Not yet recruiting
Phase	N/A
Start date	February 1, 2024
Completion date	October 1, 2027

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03548779` - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2	N/A
Completed	`NCT03292302` - Phase 1 Study of ELX-02 in Healthy Adults	Phase 1
Withdrawn	`NCT03658382` - Virtual Visits for Results Disclosure	N/A
Recruiting	`NCT02266615` - Biobank Clinical Genetics Maastricht (KG01)
Recruiting	`NCT02450851` - Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
Recruiting	`NCT05472714` - Educational Video for Genetic Testing	N/A
Recruiting	`NCT04285814` - Technology Development for Noninvasive Prenatal Genetic Diagnosis Using Whole Fetal Cells From Maternal Peripheral Blood
Completed	`NCT05443113` - Young Pectus Excavatum Patients and Genetic Defects
Completed	`NCT05655741` - Modified Delphi for Genomic Bereavement Care
Completed	`NCT03847909` - A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2	Phase 2
Completed	`NCT04584528` - Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease	N/A
Not yet recruiting	`NCT06048523` - Prospective Cohort Study of Neurogenetic Diseases	N/A
Completed	`NCT02225522` - Genomic Sequencing in Acutely Ill Neonates	N/A
Enrolling by invitation	`NCT06089954` - Penn Medicine Biobank Return of Results Program	N/A
Completed	`NCT03713333` - Implementing Digital Health in a Learning Health System	N/A
Completed	`NCT03309605` - Phase 1 Study of ELX-02 in Healthy Adult Subjects	Phase 1
Recruiting	`NCT05499091` - Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN	N/A
Completed	`NCT04556500` - Turkish Version of the Affordance in the Home Environment for Motor Development-Toddler (AHEMD-T)
Completed	`NCT04556487` - Turkish Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)
Recruiting	`NCT02551081` - Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Rehabilitation Program on Genetic and Degenerative Ataxia — RAPP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms